Immucell (ICCC) Invested Capital (2010 - 2026)

Immucell (ICCC) has reported Invested Capital for 17 consecutive years, with $41.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital rose 3.83% year-over-year to $41.2 million; the trailing twelve-month figure through Jun 2026 stood at $41.2 million (up 3.83% YoY), and the FY2025 full-year result was $36.2 million, down 5.0% from the prior year.
• Invested Capital advanced to $41.2 million in Q2 2026 per ICCC's latest filing, from $36.2 million in the prior quarter.
• Across five years, Invested Capital topped out at $44.1 million in Q1 2022 and bottomed at $34.7 million in Q2 2024.
• Historically, Invested Capital has averaged $39.2 million across 5 years, with a median of $39.7 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Invested Capital climbed 18.54% in 2022, then fell 15.4% in 2023.
• Over 5 years, Invested Capital stood at $40.6 million in 2022, then fell by 8.98% to $37.0 million in 2023, then advanced by 2.96% to $38.1 million in 2024, then decreased by 5.0% to $36.2 million in 2025, then grew by 13.91% to $41.2 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $41.2 million, $36.2 million, and $40.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.